Announcements
- Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
- Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
- Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
- Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
- Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
- Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
- Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
- Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
- Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
More ▼
Key statistics
As of last trade, Pharvaris NV (9EN:STU) traded at 15.20, 102.67% above the 52 week low of 7.50 set on Jun 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.20 |
---|---|
High | 15.20 |
Low | 15.20 |
Bid | 13.90 |
Offer | 15.10 |
Previous close | 15.10 |
Average volume | 0.00 |
---|---|
Shares outstanding | 53.82m |
Free float | 32.83m |
P/E (TTM) | -- |
Market cap | 887.17m USD |
EPS (TTM) | -2.58 USD |
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼